News
We are pleased to announce our latest news to you.
admedicum welcomes Dr. Vera Vennedey to the team
We are very pleased to welcome Vera Vennedey as Patient Engagement Consultant! Vera brings a strong background in patient preference analysis and health services research. A major project was a feasibility study of a preference analysis within the time frame of an early benefit assessment (three months) in Germany.
Read more … admedicum welcomes Dr. Vera Vennedey to the team

admedicum awarded Best Patient Engagement & Access Expert 2022 by Global Health & Pharma Biotechnology Awards
We are happy to announce that admedicum was awarded the Global Health & Pharma Biotechnology 2022 award for Best Patient Engagement & Access Expert 2022

Health Technology Assessments Framework
While there has been a centralized European marketing authorization procedure for years, Health Technology Assessments (HTA) remained decentralized at state level – this will change with the EU regulation (2021/2282) on HTA.

Drug research in Duchenne simply explained
The video was developed by admedicum in cooperation with the German Society for Muscle Diseases (Deutsche Gesellschaft für Muskelkranke e.V.) as well as patients, relatives and Dr. Blaschek. It was sponsored by Italfarmaco.

SMA Newborn Screening Alliance wins EURORDIS 2022 Patient Engagement Award
We are delighted to share with you that the European Alliance for Newborn Screening in SMA received the 2022 EURORDIS Company Award for Patient Engagement as part of the Black Pearl Awards.
Read more … SMA Newborn Screening Alliance wins EURORDIS 2022 Patient Engagement Award

admedicum supporting the SMA Newborn Screening Alliance
We are proud to be the Secretariat of the European Alliance for SMA Newborn Screening
Read more … admedicum supporting the SMA Newborn Screening Alliance

admedicum and the German Society for Muscular Diseases (DGM) are proud to announce a joint development called patient2care
We are pleased to be working a partner that is such a competent and recognized patient organization to develop a first application for patient2care

Why patient engagement matters
Hopefully you share our perspective that patient engagement should be fully integrated into drug development. If you know anyone that needs convincing that effective patient engagement in the industry matters, here is our list

Patient Preferences and the PREFER project
Patient preferences are used by Industry, Regulators, HTA/payers, academics, physicians, patients to inform decision making regarding topics like benefit/risk assessment, labeling, early access, and relevant endpoints

patient2site: Enhancing Patient Enrollment in Clinical Trials
patient2site: Technology combined with unmatched patient engagement services to create successful patient recruitment strategies, trial awareness and boost enrollment.
Read more … patient2site: Enhancing Patient Enrollment in Clinical Trials